Polish Multi-Institutional Study of Children with Ependymoma—Clinical Practice Outcomes in the Light of Prospective Trials
Authors:
- Aleksandra NapieralskaAleksandra Napieralska
- Agnieszka Mizia-MalarzAMAgnieszka Mizia-Malarz
- Weronika StolpaWSWeronika Stolpa
- Ewa PawłowskaEPEwa Pawłowska
- Małgorzata A. KrawczykMKMałgorzata A. Krawczyk
- Katarzyna Konat-BąskaKKKatarzyna Konat-Bąska
- Aneta KaczorowskaAKAneta Kaczorowska
- Arkadiusz BrąszewskiABArkadiusz Brąszewski
- Maciej HaratMHMaciej Harat
Open Access
- 14 December 2021
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 11 (12) , 2360
Abstract
We performed a multi-institutional analysis of 74 children with ependymoma to evaluate to what extent the clinical outcome of prospective trials could be reproduced in routine practice. The evaluation of factors that correlated with outcome was performed with a log rank test and a Cox proportional-hazard model. Survival was estimated with the Kaplan–Meier method. The majority of patients had brain tumours (89%). All had surgery as primary treatment, with adjuvant radiotherapy (RTH) and chemotherapy (CTH) applied in 78% and 57%, respectively. Median follow-up was 80 months and 18 patients died. Five- and 10-year overall survival (OS) was 83% and 73%. Progression was observed in 32 patients, with local recurrence in 28 cases. The presence of metastases was a negative prognostic factor for OS. Five- and 10-year progression-free survival (PFS) was 55% and 40%, respectively. The best outcome in patients with non-disseminated brain tumours was observed when surgery was followed by RTH (+/−CTH afterwards; p = 0.0001). Children under 3 years old who received RTH in primary therapy had better PFS (p = 0.010). The best outcome of children with ependymoma is observed in patients who received radical surgery followed by RTH, and irradiation should not be omitted in younger patients. The role of CTH remains debatable.Keywords
This publication has 85 references indexed in Scilit:
- A systematic review of treatment outcomes in pediatric patients with intracranial ependymomasJournal of neurosurgery. Pediatrics, 2013
- Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trialJournal of Neuro-Oncology, 2013
- Phase II study of pre‐irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2012
- Survival Benefit for Pediatric Patients With Recurrent Ependymoma Treated With ReirradiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Stereotactic radiosurgery for pediatric recurrent intracranial ependymomasJournal of neurosurgery. Pediatrics, 2010
- Intracranial Ependymomas in Children: Society of Pediatric Oncology Experience With Postoperative Hyperfractionated Local RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective studyThe Lancet Oncology, 2007
- Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Childhood EpendymomaPediatric Drugs, 2003
- Adjuvant chemotherapy of childhood posterior fossa ependymoma: Cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: A Childrens Cancer Group studyMedical and Pediatric Oncology, 1996